12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

BioChain Institute Inc., Epigenomics sales and marketing update

Epigenomics granted BioChain Chinese rights to Epigenomics' septin 9 (SEPT9) biomarker to detect colorectal cancer (CRC) in blood. BioChain said...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >